跳至主要内容
临床试验/JPRN-jRCTs061210079
JPRN-jRCTs061210079进行中(未招募)未知

Assessment of efficacy and safety of dotinurad therapy for hyperuricemic patients with kidney dysfunction - DTN-CKD study

Wada Jun0 个研究点目标入组 100 人开始时间: 2022年2月22日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1) Patients with hyperuricemia aged 20 years or older at the time of providing informed consent
  • 2) Patients who have not received treatment with uricosuric drugs within 2 weeks prior to the observation start date
  • 3) Patients with a serum uric acid level (untreated level) 8.0 mg/dL or higher within 6 weeks prior to the observation start date
  • 4) Patients with an estimated GFR (eGFR) 15 mL/min/1.73m2 or higher within 6 weeks prior to the observation start date

排除标准

  • 1) Patients with acute gouty arthritis that has not subsided
  • 2) Patients diagnosed with urolithiasis
  • 3) Patients with secondary hyperuricemia (tumor lysis syndrome, etc.)
  • 4) Patients with an AST or ALT of 100 IU/L or higher
  • 5) Patients who are pregnant, likely to be pregnant, or breastfeeding
  • 6) Patients with a history of hypersensitivity to the ingredients contained in dotinurad preparations
  • 7) Patients who are judged as inappropriate for this study by the principal investigator or subinvestigator

研究者

发起方
Wada Jun

相似试验